Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.

Trial Profile

Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Fluorouracil; Folinic acid; Folinic acid; Irinotecan; Oxaliplatin; Oxaliplatin
  • Indications Appendiceal cancer; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms COMBATAC
  • Most Recent Events

    • 10 Dec 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 17 Mar 2012 Additional lead trial centre identified as reported by EudraCT.
    • 07 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top